Law360, New York (April 26, 2010, 12:57 PM ET) -- Celgene Corp. and Novartis AG have reached a settlement with Barr Laboratories Inc. over the generic-drug maker’s attempt to market its own version of blockbuster drug Ritalin, a treatment for attention deficit hyperactivity disorder.
Judge Freda L. Wolfson of the U.S. District Court for the District of New Jersey dismissed the suit Wednesday, after U.S. regulators approved a settlement between the plaintiffs and Barr, a subsidiary of Teva Pharmaceutical Industries Ltd.
The claims and counterclaims were dismissed without prejudice, and each side agreed to pay its...
Celgene, Novartis Settle With Barr Over Generic Ritalin
To view the full article, take a free trial now.
